Illumina Accelerator


Provider of genomic sequencing instruments, consumables, and informatics with capabilities spanning next-generation sequencing (benchtop to production), microarrays, library preparation workflows, clinical sequencing services (including noninvasive prenatal screening and clinical whole-genome sequencing), and bioinformatics pipelines. Offers instrument support, training, advisory services, and medical education and research grant support for research, clinical, public-health, agrigenomics, and population-scale genomics programs.

Industries

biotechnology
genetics
health-care
medical

Nr. of Employees

Very Large (1000+)

Illumina Accelerator

San Diego, California, United States, North America


Products

Sequencing platforms and instrument reagent kits

A portfolio of sequencing systems and associated reagent kits for targeted, whole-genome, and high-throughput sequencing applications across research and clinical use cases.

High-density genotyping microarrays (including pharmacogenomics content)

Microarray assays and scanning systems for large-scale genotyping, including arrays with enhanced pharmacogenomics marker content and workflows for star-allele calling and metabolizer status reporting.

Custom and consortia genotyping arrays for agrigenomics

Pre-designed and custom genotyping arrays developed for crop, livestock, and companion-animal genomics, often delivered through collaborative consortia and supported by array-design tools.

TruSight Oncology 500 v2

A highly scalable pan-cancer, next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling (CGP) from FFPE tissue. Targets 523 genes to assess all DNA and RNA variant types (SNV, CNV, indels, fusions), plus MSI and TMB. Delivers accurate results with hybrid–capture chemistry and sophisticated bioinformatics. Reduces hands-on time and increases scalability with optional automation kits and methods. Accommodates 8-36 samples with the NextSeq 1000 and NextSeq 2000 Systems, 16-192 samples with the NovaSeq 6000 System, and 32-960 samples with the NovaSeq X Series per run.

TruSight Oncology 500 High-Throughput

A highly scalable pan-cancer, next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling (CGP) from FFPE tissue. Targets 523 genes to assess all DNA and RNA variant types (SNV, CNV, indels, fusions), plus MSI and TMB. Delivers accurate results with hybrid–capture chemistry and sophisticated bioinformatics. Reduces hands-on time and increases scalability with optional automation kits and methods. Accommodates 8-36 samples with the NextSeq 1000 and NextSeq 2000 Systems, 16-192 samples with the NovaSeq 6000 System, and 32-960 samples with the NovaSeq X Series per run.

TruSight Oncology 500 v2 Kit (48 DNA Only Samples)

A kit for library preparation and enrichment reagents for 48 DNA-only samples, optimized for cancer-related gene analysis from FFPE tissue samples.

View All Products

Services

End-to-end sequencing services for research and clinical applications, including sample collection (barcoded kits), sequencing, validated analysis, and secure delivery of results from accredited clinical laboratories.

Provision of software platforms, on-premise and cloud analytics, and accelerated secondary analysis pipelines for sequence processing, variant calling, and cohort-level analyses.

On-site and remote service contracts for instrument installation qualification, preventive maintenance, proactive performance monitoring, and technical support.

Consulting and program support for design and implementation of population-scale genomics initiatives, covering lab workflows, informatics architecture, governance, and economic modeling.

Expertise Areas

  • Next-generation sequencing platforms and reagents
  • Clinical genomics and diagnostic sequencing (accredited laboratory operations)
  • Noninvasive prenatal screening (cfDNA, genome-wide NIPT)
  • Microbial genomics and public-health genomic surveillance
  • Show More (7)

Key Technologies

  • Next-generation sequencing (NGS)
  • Sequencing-by-synthesis chemistry
  • Whole-genome cfDNA sequencing for screening
  • Paired-end sequencing
  • Show More (7)

News & Updates

Webinar focused on instrument monitoring and utilization to reduce downtime.

Feature article on a partnership supporting Brain Fest at Science Centre Singapore and STEM outreach efforts.

Research publication describing integrated NGS approaches for genotyping relevant to carrier screening.

Reported installed base of more than 22,000 systems and over 300,000 studies driven by the company's technology (2022 reference).

Reported portfolio of approximately 9,000 patents.

Reported annual revenue of $4.3B USD (as of 2024).


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.